Marketing: Page 2

Bluebird resumes marketing gene therapy in Europe

Zynteglo sales have been on hold since February, when a patient in a clinical trial of another, related Bluebird medicine developed leukemia.

By Jacob Bell • July 09, 2021

Biohaven beats expectations with fast sales of migraine drug

Second quarter sales of Nurtec ODT, which recently became the first migraine drug cleared for acute and preventive treatment, were nearly twice what analysts on Wall Street had predicted. 

By Ned Pagliarulo • July 08, 2021

FDA revises labeling of Biogen's Alzheimer's drug to emphasize early treatment

Aduhelm's approval last month, already highly controversial, was made more so by the agency's decision to clear the drug for a broad group of patients. New prescribing information more closely matches clinical testing criteria.

By Ned Pagliarulo , Ben Fidler • July 08, 2021

WHO backs Roche, Sanofi drugs for COVID-19 after research ups and downs

Once long-shot experiments in the rush to repurpose drugs for COVID-19, both Actemra and Kevzara could become more widely used, renewing questions around cost and access.

By Ben Fidler • July 07, 2021

Nestlé joins Seres in deal to market microbiome drug

The health science unit at Nestlé may pay more than $500 million to secure rights in the U.S. and Canada for SER-109, a spore-filled capsule meant for patients with recurrent C. diff infections.

By Kristin Jensen • July 01, 2021

ICER stands by view on Biogen's Aduhelm, says sharp price cut needed

The influential nonprofit maintains that the clinical trial evidence supporting Aduhelm is insufficient to prove a health benefit. But if some efficacy is assumed, ICER argues Biogen's $56,000 price tag is far too high.

By Ned Pagliarulo • June 30, 2021

How biopharma innovation may benefit from more inclusive print communications

Medical advancements are evolving at a rapid pace, and so is public consumption of information.

European regulators push 8 drugs toward approval, including controversial anemia pill

A key committee of the EMA gave a positive review of Astellas and Fibrogen's roxadustat, as well as Bristol Myers Squibb's cell therapy Abecma and UCB's psoriasis drug Bimzelx.

By Jacob Bell • June 25, 2021

As 5 Blue Cross Blue Shield plans join to tackle drug prices, some remain skeptical

Another healthcare venture promises to lower costs, this time by using patient data on drug efficacy through a handful of large insurers.

By Samantha Liss • June 23, 2021

Anthem joins insurer-backed generics effort CivicaScript

The subsidiary of hospital-owned nonprofit CivicaRx plans to make six to 10 common generic drugs that don't have enough competition to drive down cost.

By Rebecca Pifer • June 16, 2021

Clinical leadership: A foundational double attack strategy

We define the most influential clinicians as Clinical Leaders, those who measurably impact the clinical behavior of other clinicians in their "clinical networks."

A first-of-its-kind Alzheimer's drug raises heavy questions around who will and won't get it

Biogen priced its newly approved medicine Aduhelm at an average cost of $56,000 a year, adding affordability to other barriers patients may face. 

By Jacob Bell • June 08, 2021

Moving pharma marketing from multichannel to omnichannel

IQVIA experts weigh in on the importance of an omnichannel approach.

FDA restricts use of Intercept drug due to liver injury risk

An investigation linked the drug to severe injuries in about two dozen patients, leading the agency to add a new contraindication to the label.

By Kristin Jensen • May 27, 2021

ICER, vocal critic of drug company pricing, turns scrutiny to insurers

The watchdog group plans to examine how cost sharing can hurt access to care, but it won't assess some of the most controversial insurer practices.

By Jonathan Gardner • May 25, 2021

Pfizer, BioNTech to send EU up to 1.8B coronavirus vaccine doses

The deal, which the companies and the bloc have been negotiating for weeks, will significantly expand on the current contract for 600 million shots.

By Kristin Jensen • May 20, 2021

Humira patents take center stage as House panel targets AbbVie pricing

CEO Richard Gonzalez defended the company's practices, arguing its profits help spur innovation: "The products that are on the market today pay for the products of the future," he said.

By Jonathan Gardner • May 18, 2021

6 tips to deliver information that matters using print communications

As remote work continues, print is as important as ever for biopharmaceutical companies when it comes to reaching a varied audience that may include patients, doctors' offices, researchers, and internal staff.

Top customer engagement trends in pharma

The future of provider and patient engagement in healthcare.

CDC panel endorses Pfizer vaccine for 12- to 15-year-olds

The vote, which the CDC officially adopted hours after, gives a clear green light for states to begin vaccinating younger adolescents with the shot. 

By Ned Pagliarulo • UPDATED: May 13, 2021 at 10:01 a.m.

Amgen asks FDA for approval of key asthma drug

Tezepelumab is one of Amgen's top experimental medicines and a U.S. OK would help its efforts to offset revenue declines from its aging blockbusters.

By Ned Pagliarulo • May 10, 2021

FDA, CDC support resuming use of J&J vaccine after advisory panel vote

While health officials have documented more cases of a rare blood clotting syndrome associated with J&J's vaccine, a CDC committee supported use of the shot with an added warning. 

By Ned Pagliarulo , Ben Fidler • UPDATED: April 23, 2021 at 7:14 p.m.

A year with COVID-19: The impact of data on pharma marketing

Learn how three pharma brands used data to validate and adjust their promotional spend in 2020.

Biden administration hikes Medicare reimbursement for coronavirus vaccines

The increased payout by Medicare is intended to speed up distribution of the three currently available shots.

By Shannon Muchmore • March 16, 2021

The essential audience for well-being

For marketers in the health space, cannabis and CBD consumers represent an audience that is in search of both alternative and conventional methods of well-being as their transformation from patient to participant accelerates.